Castrate Resistant Prostate Cancer: Post-Docetaxel Management

Por Zhao, Song, Yu, Evan Y.
Publicado no Curr Opin Urol (2013)

Persistent androgen receptor addiction in castration-resistant prostate cancer

Por Schweizer, Michael T., Yu, Evan Y.
Publicado no J Hematol Oncol (2015)

Targeting intratumoral androgens: statins and beyond

Por Schweizer, Michael T., Yu, Evan Y.
Publicado no Ther Adv Med Oncol (2016)

AR-Signaling in Human Malignancies: Prostate Cancer and Beyond

Por Schweizer, Michael T., Yu, Evan Y.
Publicado no Cancers (Basel) (2017)

The metastatic castration-resistant prostate cancer treatment paradigm: more choices, more questions

Por Yu, Evan Y, Oh, William K
Publicado em 2014

Progress in understanding what is being statin(ed) in prostate cancer

Por Ramos, Jorge D., Yu, Evan Y.
Publicado no JAMA Oncol (2015)

Delayed Antiandrogen Withdrawal Syndrome After Discontinuation of Bicalutamide

Por Cowan, Andrew J., Inoue, Yoshio, Yu, Evan Y.
Publicado no Clin Genitourin Cancer (2014)

Improved disease markers suggest dual response in a patient with metastatic castration resistant prostate cancer and chronic lymphocytic leukemia following active cellular immunoth...

Por Cheng, Heather H., Soleau, Colleen, Yu, Evan Y.
Publicado no J Hematol Oncol (2015)

Long-term survival in bone-predominant metastatic urothelial carcinoma

Por Ramos, Jorge D., Cheng, Heather H., Yu, Evan Y.
Publicado no Clin Genitourin Cancer (2014)

Docetaxel-Related Toxicity in Metastatic Hormone-Sensitive and Metastatic Castration-Resistant Prostate Cancer

Por Schweizer, Michael T., Gulati, Roman, Mostaghel, Elahe A., Nelson, Peter S., Montgomery, R. Bruce, Yu, Evan Y., Cheng, Heather H.
Publicado no Med Oncol (2016)

Detection of Previously Unidentified Metastatic Disease as a Leading Cause of Screening Failure in a Phase III Trial of Zibotentan Versus Placebo in Patients with Nonmetastatic, Ca...

Por Yu, Evan Y., Miller, Kurt, Nelson, Joel, Gleave, Martin, Fizazi, Karim, Moul, Judd W., Nathan, Faith E., Higano, Celestia S.
Publicado em 2012

Relationships between times to testosterone and prostate-specific antigen rises during the first “off treatment” interval of intermittent androgen deprivation are prognostic for ca...

Por Kuo, Kevin F., Hunter-Merrill, Rachel, Gulati, Roman, Hall, Suzanne P., Gambol, Teresa E., Higano, Celestia S., Yu, Evan Y.
Publicado no Clin Genitourin Cancer (2014)

Duration of First Off-Treatment Interval Is Prognostic for Time to Castration Resistance and Death in Men With Biochemical Relapse of Prostate Cancer Treated on a Prospective Trial...

Por Yu, Evan Y., Gulati, Roman, Telesca, Donatello, Jiang, Peter, Tam, Stephen, Russell, Kenneth J., Nelson, Peter S., Etzioni, Ruth D., Higano, Celestia S.
Publicado em 2010

Long-Term Dynamics of Bone Mineral Density During Intermittent Androgen Deprivation for Men With Nonmetastatic, Hormone-Sensitive Prostate Cancer

Por Yu, Evan Y., Kuo, Kevin F., Gulati, Roman, Chen, Shu, Gambol, Teresa E., Hall, Suzanne P., Jiang, Peter Y., Pitzel, Peggy, Higano, Celestia S.
Publicado em 2012

C11-Acetate and F-18 FDG PET for Men With Prostate Cancer Bone Metastases: Relative Findings and Response to Therapy

Por Yu, Evan Y., Muzi, Mark, Hackenbracht, Joy A., Rezvani, Brian B., Link, Jeanne M., Montgomery, Robert Bruce, Higano, Celestia S., Eary, Janet F., Mankoff, David A.
Publicado em 2011

Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer

Por Lee, Franklin C., Harris, William, Cheng, Heather H., Shenoi, Jaideep, Zhao, Song, Wang, Junfeng, Champion, Thomas, Izard, Jason, Gore, John L., Porter, Michael, Yu, Evan Y., Wright, Jonathan L.
Publicado em 2013

Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer

Por Yu, Evan Y., Wilding, George, Posadas, Edwin, Gross, Mitchell, Culine, Stephane, Massard, Christophe, Morris, Michael J., Hudes, Gary, Calabrò, Fabio, Cheng, Shinta, Trudel, Géralyn C., Paliwal, Prashni, Sternberg, Cora N.
Publicado em 2009

Once-daily Dasatinib: Expansion of Phase II Study Evaluating Safety and Efficacy of Dasatinib in Patients With Metastatic Castration-resistant Prostate Cancer

Por Yu, Evan Y., Massard, Christophe, Gross, Mitchell E., Carducci, Michael A., Culine, Stephane, Hudes, Gary, Posadas, Edwin M., Sternberg, Cora N., Wilding, George, Trudel, Géralyn C., Paliwal, Prashni, Fizazi, Karim
Publicado em 2011

Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate

Por Schweizer, Michael T., Cheng, Heather H., Tretiakova, Maria S., Vakar-Lopez, Funda, Klemfuss, Nola, Konnick, Eric Q., Mostaghel, Elahe A., Nelson, Peter S., Yu, Evan Y., Montgomery, Bruce, True, Lawrence D., Pritchard, Colin C.
Publicado no Oncotarget (2016)

Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer

Por Kuo, Calvin J., Farnebo, Filip, Yu, Evan Y., Christofferson, Rolf, Swearingen, Rebecca A., Carter, Robert, von Recum, Horst A., Yuan, Jenny, Kamihara, Junne, Flynn, Evelyn, D'Amato, Robert, Folkman, Judah, Mulligan, Richard C.
Publicado em 2001